Critical Reviews in Oncology Hematology Critical Reviews in Oncology Hematology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Biological aspects of chondrosarcoma: leaps and hurdles
Chondrosarcomas are characterized by their chemo- and radioresistance leading to a therapeutic surgical approach which remains the only available treatment with a 10-year survival between 30% and 80% depending on the grade. Non-surgical treatments are under investigation and rely on an accurate biological understanding of drug resistance mechanisms. Novel targeted therapy which represents a new relevant therapeutic approach will open new treatment options by targeting several pathways responsible for processes of proliferation and invasion. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 22, 2018 Category: Cancer & Oncology Authors: Beno îte Mery, Sophie Espenel, Jean-Baptiste Guy, Chloé Rancoule, Alexis Vallard, Marie-Thérèse Aloy, Claire Rodriguez-Lafrasse, Nicolas Magné Source Type: research

When and how to treat women with HER2-positive, small (pT1a-b), node-negative breast cancer?
Breast cancer is the most common type of cancer among women in the United States and Western Europe (Siegel et al., 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 22, 2018 Category: Cancer & Oncology Authors: Stefania Gori, Monica Turazza, Alessandra Modena, Simona Duranti, Giuseppe Zamboni, Filippo Alongi, Giovanni Carbognin, Alberto Massocco, Matteo Salgarello, Alessandro Inno Source Type: research

Meeting the needs of breast cancer: a nucleolin ’s perspective
Nucleolin has emerged in the cancer scene as a potential target. Nucleolin participates in various cellular functions controlling different components of RNA and DNA metabolism, including ribosome biogenesis, ribosomal (r)RNA maturation, ribosomal (r)DNA transcription and chromatin structure (Ginisty et al., 1999; Srivastava and Pollard, 1999). Therefore, nucleolin is mainly located at the dense fibrillar and granular regions of the nucleolus and nucleoplasm (Lischwe et al., 1981). Nonetheless, different pools of nucleolin, in the cytoplasm and cell membrane, have also been demonstrated to exhibit important functions (Sriv...
Source: Critical Reviews in Oncology Hematology - March 22, 2018 Category: Cancer & Oncology Authors: Ana C. Greg ório, Manuela Lacerda, Paulo Figueiredo, Sérgio Simões, Sérgio Dias, João Nuno Moreira Source Type: research

EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale
EpCAM, known as an epithelial cell adhesion molecule, plays an essential role in cell adhesion, migration, metastasis and cell signalling. Rather than acting as an apoptosis antagonist, it induces cellular proliferation that impacts the cell cycle, and as a signalling transducer it uses and enhances the Wnt pathway, which is significantly relevant in cell renewal and cancer. EpCAM has become a marker of circulating tumour cells (CTCs) in lung cancer due to its specificity, and its high and stable expression level. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 22, 2018 Category: Cancer & Oncology Authors: Alejandro Herreros Pomares, Crist óbal Aguilar-Gallardo, Silvia Calabuig-Fariñas, Rafael Sirera, Eloísa Jantus-Lewintre, Carlos Camps Source Type: research

Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Melanoma is a disease haunting mankind for centuries and the proofs documented in the literature can be traced back to 1600s. The incidences of metastatic melanomas are growing steadily ultimately leading to increase in the mortality rate in comparison to other cancers (Hodi et al., 2010). The initial standard therapies for metastatic melanomas were chemotherapy like dacarbazine, interleukin 2, surgery etc., but could not perform well over the time. Nearly 50% of the patients suffering from melanomas have mutation in BRAF gene (encodes B-Raf protein, a member of Raf kinase family of growth signal transduction protein kinas...
Source: Critical Reviews in Oncology Hematology - March 19, 2018 Category: Cancer & Oncology Authors: Mohd Wahid, Arshad Jawed, Raju K. Mandal, Sajad A. Dar, Naseem Akhter, Pallavi Somvanshi, Farah Khan, Mohtashim Lohani, Mohammed Y. Areeshi, Shafiul Haque Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 14, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review
To describe the current state of knowledge concerning the quality of reporting in phase II clinical trials in oncology and to describe the various methods published allowing this quality evaluation. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 10, 2018 Category: Cancer & Oncology Authors: Romain Rivoirard, Julien Langrand-Escure, Mathieu Oriol, Fabien Tinquaut, Franck Chauvin, Chlo é Rancoule, Nicolas Magné, Aurélie Bourmaud Source Type: research

Evaluation of the quality of the reporting of phase II clinical trials in oncology: a systematic review
To describe the current state of knowledge concerning the quality of reporting in phase II clinical trials in oncology and to describe the various methods published allowing this quality evaluation. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 10, 2018 Category: Cancer & Oncology Authors: Romain Rivoirard, Julien Langrand-Escure, Mathieu Oriol, Fabien Tinquaut, Franck Chauvin, Chlo é Rancoule, Nicolas Magné, Aurélie Bourmaud Source Type: research

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis
At present, there is uncertainty on the best systemic treatment in first-line setting for RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. Indeed, several chemotherapy and biologics combinations showed an improvement on survival. We performed a systematic review with a pair-wise and bayesan meta-analysis to rank the best strategy for these patients. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 9, 2018 Category: Cancer & Oncology Authors: Domenico Ciliberto, Nicoletta Staropoli, Francesca Caglioti, Silvia Chiellino, Antonella Ierardi, Rossana Ingargiola, Cirino Botta, Mariamena Arbitrio, Pierpaolo Correale, Pierfrancesco Tassone, Pierosandro Tagliaferri Source Type: research

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: a classic and Bayesian meta-analysis
At present, there is uncertainty on the best systemic treatment in first-line setting for RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. Indeed, several chemotherapy and biologics combinations showed an improvement on survival. We performed a systematic review with a pair-wise and bayesan meta-analysis to rank the best strategy for these patients. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 9, 2018 Category: Cancer & Oncology Authors: Domenico Ciliberto, Nicoletta Staropoli, Francesca Caglioti, Silvia Chiellino, Antonella Ierardi, Rossana Ingargiola, Cirino Botta, Mariamena Arbitrio, Pierpaolo Correale, Pierfrancesco Tassone, Pierosandro Tagliaferri Source Type: research

Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials
Ovarian cancer (OC) represents, for incidence, the sixth most common cancer worldwide, and it is characterized by poor prognosis (Torre et al., 2016). Intravenous 3-weekly carboplatin and paclitaxel remain the standard chemotherapy drugs for first-line therapy in advanced OC, after complete cytoreductive surgery is achieved (Anon., 2017a). Over the ears, modifications in adjuvant chemotherapy regimen, including dose-dense schedules, have been investigated in different trials and provided conflicting results regarding clinical outcomes and toxicity. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 7, 2018 Category: Cancer & Oncology Authors: C. Marchetti, F. De Felice, A. Di Pinto, O. D ’Oria, N. Aleksa, A. Musella, I. Palaia, L. Muzii, V. Tombolini, P. Benedetti Panici Source Type: research

Circulating tumor cells count as a predictor of survival in lung cancer
The presence of circulating tumor cells (CTCs) in the peripheral blood of cancer patients was first described in the second half of the 19th century, but research interest in their potential clinical utility has intensified and greatly expanded only in recent years. Herein, we summarize and critically discuss current knowledge on CTC count as a predictor of survival in lung cancer, and comment on the existing challenges and future perspectives in this field. The majority of data published to date, including the results of almost all large cohorts, are strongly supportive of the value of CTC enumeration as a predictor of su...
Source: Critical Reviews in Oncology Hematology - March 7, 2018 Category: Cancer & Oncology Authors: Konstantinos Syrigos, Oraianthi Fiste, Andriani Charpidou, Dimitra Grapsa Source Type: research

Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 7, 2018 Category: Cancer & Oncology Authors: C. Marchetti, F. De Felice, A. Di Pinto, O. D ’Oria, N. Aleska, A. Musella, I. Palaia, L. Muzii, V. Tombolini, P. Benedetti Panici Source Type: research

Circulating Tumor Cells Count as a Predictor of Survival in Lung Cancer
The presence of circulating tumor cells (CTCs) in the peripheral blood of cancer patients was first described in the second half of the 19th century, but research interest in their potential clinical utility has intensified and greatly expanded only in recent years. Herein, we summarize and critically discuss current knowledge on CTC count as a predictor of survival in lung cancer, and comment on the existing challenges and future perspectives in this field. The majority of data published to date, including the results of almost all large cohorts, are strongly supportive of the value of CTC enumeration as a predictor of su...
Source: Critical Reviews in Oncology Hematology - March 7, 2018 Category: Cancer & Oncology Authors: Konstantinos Syrigos, Oraianthi Fiste, Andriani Charpidou, Dimitra Grapsa Source Type: research